Endocrine therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A case report

Anna Kornietskaya; Sevindzh Evdokimova; Andrei Kachmazov; Alexander Fedenko; Larisa Bolotina; Dmitriy Sidorov; Nadezhda Volchenko; Natalia Goeva; Anastasia Govaleshko; Andrey Kaprin

doi:10.3389/fonc.2022.970142

Endocrine therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A case report

Front Oncol. 2022 Sep 13:12:970142. doi: 10.3389/fonc.2022.970142. eCollection 2022.

Affiliations

¹ P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.
² City Clinical Oncological Hospital No1, Moscow, Russia.
³ Peoples' Friendship University of Russia, Moscow, Russia.

Abstract

Solid pseudopapillary neoplasm (SPN) of the pancreas is an extremely rare tumor, associated with favorable prognosis and long-term survival in patients with advanced disease. However, limited data exist on systemic therapy for such patients. Herein, we present a case of a young woman with a history of SPN, who progressed after multiple surgical resections and chemotherapy regimens. The immunohistochemistry (IHC) showed overexpression of estrogen receptors (ER) and progesterone receptors (PR) in tumor tissue. The patient started to receive tamoxifen and showed a durable response to endocrine therapy.

Keywords: case report; endocrine therapy; pancreas; solid pseudopapillary neoplasm (SPN); tamoxifen.

Publication types

Case Reports